Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous erythrocyte exosomes are extracellular vesicles isolated from a patient's own red blood cells (erythrocytes), utilized for their potential to enhance tissue repair and regeneration. In the context of dental medicine, they are being investigated by The First Affiliated Hospital of Ji'nan University for the treatment of periodontitis and peri-implant bone defects. These exosomes are typically loaded into a carrier, such as a collagen sponge or concentrated growth factor (CGF) gel, and implanted into the site of the defect. They are thought to promote healing by delivering regenerative signals that stimulate osteogenesis and reduce local inflammation, facilitating the repair of bone and soft tissue defects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous erythrocyte exosomes.